Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19949143 | 0.85 | DGAT1 (0.33) | DGAT1MAPT | |
| SCHEMBL19948747 | 0.81 | DGAT1 (0.33) | DGAT1CNR2AXL | |
| SCHEMBL30259749 | 0.80 | DGAT1 (0.33) | DGAT1MAPT | |
| SCHEMBL19948718 | 0.79 | RET (0.40) | DGAT1AXLTYRO3MERTK | |
| SCHEMBL27075020 | 0.79 | DGAT1 (0.34) | DGAT1MAPTKLKB1 | |
| SCHEMBL19948808 | 0.78 | DGAT1 (0.32) | DGAT1MAPT | |
| SCHEMBL30968077 | 0.78 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL21808512 | 0.76 | FGFR2 (0.39) | DGAT1KLKB1 | |
| SCHEMBL30767298 | 0.75 | FGFR2 (0.45) | DGAT1KLKB1 | |
| SCHEMBL21846662 | 0.75 | FGFR2 (0.45) | DGAT1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | DGAT1 4084/4885MAPT 3980/4885CNR2 4748/4885 |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | DGAT1 4059/4885MAPT 4245/4885CNR2 4713/4885 |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, MAPKAPK5 | DGAT1 4084/4885MAPT 3980/4885CNR2 4748/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | DGAT1 4059/4885MAPT 4245/4885CNR2 4713/4885 |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | DGAT1 4059/4885MAPT 4245/4885CNR2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.